**SUPPLEMENTARY DATA:**

**Supplementary tables:**

1. **Supplementary table 1**
2. **Supplementary table 2**

**This supplementary material has been provided by the authors to give readers additional information about their work.**

|  |
| --- |
| **Supplementary Table1. List of studies with information on regression analysis in AP**  |
| S No. | **Author Year** | **Information on regression analysis** |
|   | **Asian Studies** |
| 1 | Kondo 2014 | Univariate and multivariate analyses for prognostic factors influencing cancer-specific survival were performed using the Cox proportional hazards model |
| 2 | Lee 2015 | Continuous variables were compared using the Mann– Whitney U-test. Kaplan–Meier estimates and the Cox proportional hazard model were used in the analysis of time-event variables. |
| **Supplementary table 2. Hazards Ratio in the AP**  |
| **Asian Studies** |   |   |   |   |
| **Author Year** | **Variable** | **Hazards ratio** | **95% CI** | **P value** |
| Kondo 2014 | Median PFS of Schedule 2/1 group> Schedule 4/2 group (n=48) | 0.57 | 0.23–1.35 | 0.2 |
|   | **Prognostic factors influencing PFS (Multivariate analysis)** |
|   | Papillary subtype | 17.23 |  1.98–122.2  | 0.01 |
|   | Prior nephrectomy  | 0.39 | 0.14–1.18  | 0.09 |
|   | Memorial Sloan-Kettering Cancer Centre poor risk  | 2.25 | 0.83–5.49  | 0.1 |
|   | Schedule 2/1  | 0.57 | 0.23–1.35  | 0.2 |
|   | Age  | 7.22 | 0.48–135.7 | 0.15 |
|   |   |   |   |   |
| Lee 2015 | Failure-free survival at 6 months (schedule 2/1 vs. schedule 4/2) | 0.57 | 0.34 – 0.95 | 0.029 |
|   | Time to progression | 0.75 | 0.44 – 1.27 |  |
|   | OS (schedule 2/1 vs. schedule 4/2) | 1.15 | 0.64-2.04 |   |
|   | probability of dose reduction  | 0.35 | 0.16-0.61 | 0.014 |

CI, Confidence Interval; PFS, Progression-free survival; OS, Overall survival